Benitec Biopharma (FRA:BJ9) Total Stockholders Equity : €10.58 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Benitec Biopharma Total Stockholders Equity?

Benitec Biopharma's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €10.58 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Benitec Biopharma's Book Value per Share for the quarter that ended in Mar. 2024 was €0.03. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Benitec Biopharma's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.03.

Benitec Biopharma Total Stockholders Equity Historical Data

The historical data trend for Benitec Biopharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Total Stockholders Equity Chart

Benitec Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Stockholders Equity

Get a 7-Day Free Trial

14.69

9.09

16.61

2.73

0.19

Benitec Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															4.40	0.19	20.90	14.19	10.58

Benitec Biopharma (FRA:BJ9) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Benitec Biopharma's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(10.58	-	0)	/	321.287
	=	0.03

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Benitec Biopharma's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.269	+	0.057)	/	10.58
	=	0.03

Benitec Biopharma Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Benitec Biopharma (FRA:BJ9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (FRA:BJ9) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

BNTC:USA

Address

3940 Trust Way, Hayward, CA, USA, 94545

Website

https://www.benitec.com

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Benitec Biopharma (FRA:BJ9) Headlines

No Headlines